Text Size

Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Renovo.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Renovo
ClinicalTrials.gov Identifier:
NCT00432211
First received: February 6, 2007
Last updated: February 3, 2009
Last verified: February 2009
History of Changes

February 6, 2007
February 3, 2009
May 2006
July 2008   (final data collection date for primary outcome measure)
  • Investigator scar assessment [ Time Frame: up to 7 month visit ] [ Designated as safety issue: No ]
  • Patient scar assessment [ Time Frame: up to 7 month visit ] [ Designated as safety issue: No ]
  • Independent scar assessment [ Time Frame: up to month 7 ] [ Designated as safety issue: No ]
  • Investigator scar assessment
  • Patient scar assessment
  • Independent scar assessment
Complete list of historical versions of study NCT00432211 on ClinicalTrials.gov Archive Site
  • Local tolerability [ Time Frame: up to month 7 ] [ Designated as safety issue: Yes ]
  • Adverse events [ Time Frame: up to month 7 ] [ Designated as safety issue: Yes ]
  • Local tolerability
  • Adverse events
Not Provided
Not Provided
 
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.

This study is being undertaken to investigate the efficacy and safety of Juvista (given as an intradermal injection of 200ng/100µl per linear centimetre of wound margin) in the prevention or improvement of scar appearance when administered intradermally to approximated wound margins following surgical scar revision.

In addition, this study will compare the scar revision techniques of complete excision (excision of the entire scar during one surgical procedure) and staged excision (excision of the outmost segments and central core separately).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cicatrix
Drug: Avotermin

Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.

Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration.
  • Placebo Comparator: 1
    Complete Scar Excision
    Intervention: Drug: Avotermin
  • Placebo Comparator: 2
    Staged Excision of scar
    Intervention: Drug: Avotermin
So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G, Mason T, Metcalfe A, O'kane S, Ferguson MW. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg. 2011 Jul;128(1):163-72.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
September 2012
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects aged 18-85 years who have provided written informed consent.
  • A body mass index between 15 and 35 kg/m2 .
  • Subjects with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.
  • Female subjects of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until one month after administration of the final study dose.
  • Subjects with linear scars that, in the opinion of the Investigator, are suitable for revision by excision and direct closure. The area of scar to be revised must be at least 5cm in length and have at least two comparable areas.
  • Subjects, who, in the opinion of the Investigator have stabilised, mature scars.

Exclusion Criteria:

  • Subjects who on direct questioning and physical examination have history or evidence of keloid scarring.
  • Subjects with scars for revision that cross a joint or are in close proximity to an anatomical structure, which could lead to distortion of the resultant scar.
  • Subjects with additional scars less than 3cm away from the area to be revised.
  • Subjects with a history of a bleeding disorder.
  • Subjects with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerability or efficacy.
  • Subjects who have had surgery in the area to be excised within one year of Day 0.
  • Subjects with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
  • Subjects who on direct questioning and / or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.
  • Subjects with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
  • Subjects who are taking, or have taken, any investigational drugs including Juvista within 3 months prior to the screening visit.
  • Subjects who are taking regular, continuous, oral corticosteroid therapy.
  • Subjects who, in the opinion of the Investigator, have significant ongoing psychiatric disorders, which may interfere with the trial assessments / visits.
  • Subjects undergoing investigations or changes in management for an existing medical condition.
  • Subjects who are or who become pregnant up to and including Day 0 or who are lactating.
  • In the opinion of the Investigator, a subject who is not likely to complete the trial for whatever reason.
Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00432211
RN1001-319-1009
Not Provided
Renovo Ltd
Renovo
Not Provided
Principal Investigator: D A McGrouther, FRCS MD University of Manchester
Renovo
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP